Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 28, 2009

Duke University to Use WaferGen’s Real-Time PCR System to Validate Cancer SNPs

  • Duke University Medical Center scientists inked a research collaboration to use WaferGen Biosystems’ SmartChip™ Real-Time PCR System in cancer-related genotyping.  WaferGen believes the SmartChip Real-Time PCR System will be the first platform to combine the high-throughput capability and cost efficiencies of existing microarrays with the sensitivity and accuracy of real-time PCR. 

    Under terms of the collaboration, the laboratory of John A. Olson Jr., M.D., Ph.D., and Jeffrey R. Marks, Ph.D., at the Institute for Genome Sciences and Policy will conduct genotyping projects using the technology to validate SNPs related to breast cancer.  Additionally, researchers will aim to examine the impact the validated SNPs have on patients’ disease prognosis and response to treatment.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »